View Post

‘Unprecedented’ 73% Response Rate With Combo in Untreated RCC

In In The News by Barbara Jacoby

By: Nick Mulcahy From: medscape.com The combination of an immunotherapy and a vascular endothelial growth factor (VEGF) inhibitor resulted in a groundbreaking response rate in metastatic renal cell carcinoma (RCC), according to results of an ongoing phase 1b study. In a cohort of treatment-naive patients, 38 of 52 (73%) achieved an objective response, including 4 complete responses, with the combination …

View Post

Combination Immunotherapy Set to Become Integral Element of Renal Cell Carcinoma Treatment

In In The News by Barbara Jacoby

Merck KGaA and Pfizer’s Phase III JAVELIN Renal 101 trial, which will assess the combination of the checkpoint inhibitor avelumab and Pfizer’s anti-angiogenesis tyrosine kinase inhibitor (TKI) Inlyta (axitinib) in the first-line renal cell carcinoma (RCC) setting, is the most likely immunotherapy combination to be first to market in the treatment space, according to an analyst with research and consulting …

View Post

Snoring linked to worse cancer outcomes in new research

In In The News by Barbara Jacoby

By: Tai Fox From: independent.co.uk There may be more worrying consequences to loud snoring than just keeping your family up all night. A link has been made between sleep apnoea – which is often indicated by loud snoring – and worse cancer outcomes in recent studies. Sleep apneoa is a common disorder where an individual has more pauses in breathing patterns or has …